The first tissue-free MRD test for CRC,
now available for breast and lung cancers.1-5
Interrogate thousands of genomic and epigenomic signals to achieve high sensitivity without tissue dependency.1,2
Results in 2-3 weeks.⁶*
Detect minimal residual disease¹
Monitor ctDNA to help predict recurrence.¹
Important Note: The Guardant Reveal test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Guardant Reveal refers to Guardant Reveal Laboratory Developed Test (LDT). This test has not been cleared or approved by the US FDA.
CRC, colorectal cancer; ctDNA, circulating tumor DNA; MRD, minimal residual disease.
*Turnaround time (TAT) varies by cancer type. TAT for CRC is within 2 weeks of sample receipt. TAT for breast and lung cancers is within 3 weeks of sample receipt.
Home Guardant Infinity™ for HCPs Treatment Selection Monitoring and MRD Assessment Guardant Infinity™ for BioPharma